BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 23064955)

  • 1. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
    Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
    Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
    Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
    Sato Y; Takayama T; Sagawa T; Takahashi Y; Ohnuma H; Okubo S; Shintani N; Tanaka S; Kida M; Sato Y; Ohta H; Miyanishi K; Sato T; Takimoto R; Kobune M; Yamaguchi K; Hirata K; Niitsu Y; Kato J
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):721-8. PubMed ID: 20041328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
    Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
    Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
    Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
    Kakeji Y; Oki E; Egashira A; Sadanaga N; Takahashi I; Morita M; Emi Y; Maehara Y
    Oncology; 2009; 77(1):49-52. PubMed ID: 19556809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
    Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination.
    Shigeyasu K; Kagawa S; Uno F; Nishizaki M; Kishimoto H; Gochi A; Kimura T; Takahata T; Nonaka Y; Ninomiya M; Fujiwara T
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):937-43. PubMed ID: 23355040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
    Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
    Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer.
    Kunisaki C; Takahashi M; Makino H; Oshima T; Fujii S; Takagawa R; Kimura J; Kosaka T; Ono HA; Akiyama H; Kameda K; Kito F; Morita S; Endo I
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1363-8. PubMed ID: 20803016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
    Baba E; Esaki T; Ariyama H; Mitsugi K; Morikita T; Fujishima H; Kusaba H; Nakano S; Akashi K
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):611-7. PubMed ID: 21116623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer.
    Tsutani Y; Ohara M; Suzuki T; Minami K; Miyahara E; Kameda A; Noso Y
    Anticancer Res; 2009 Jul; 29(7):2775-9. PubMed ID: 19596960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer.
    Kim YH; Seo HY; Jeen YT; Kim HK; Shim BY; Yang J
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):253-60. PubMed ID: 18493761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
    Koizumi W; Nakayama N; Tanabe S; Sasaki T; Higuchi K; Nishimura K; Takagi S; Azuma M; Ae T; Ishido K; Nakatani K; Naruke A; Katada C
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):407-13. PubMed ID: 21796483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age.
    Zang DY; Yang DH; Lee HW; Hwang SW; Song HH; Jung JY; Kwon JH; Kim HJ; Kim JH; Park SR; Kim MJ; Jang KM; Park CK; Kim JH; Lee BH
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):509-16. PubMed ID: 18481067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer].
    Yoshida K; Wada Y; Tanabe K; Ukon K; Hihara J
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():83-6. PubMed ID: 16897978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biweekly Docetaxel and S-1 combination chemotherapy as first-line treatment for elderly patients with advanced gastric cancer.
    Kunisaki C; Takahashi M; Ono HA; Hasegawa S; Tsuchida K; Oshima T; Ota M; Fukushima T; Tokuhisa M; Izumisawa Y; Takagawa R; Kimura J; Kosaka T; Makino H; Akiyama H; Endo I
    Anticancer Res; 2013 Feb; 33(2):697-704. PubMed ID: 23393370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.